Article Text


A6.1 Antibody Response Against Porphyromonas Gingivalis and Matrix Metalloproteinase-3 are Associated with Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis, but only Matrix Metalloproteinase-3 is a Predictive Factor of Response to Infliximab
  1. M Rinaudo-Gaujous1,
  2. P Miossec2,
  3. V Blasco-Baque3,
  4. P Gaudin4,
  5. T Thomas5,
  6. A Moreau1,
  7. C Genin1,
  8. S Paul*,1,
  9. H Marotte*,5
  1. 1Laboratory of Immunology and Immunomonitoring, CIC CIE3 Inserm Vaccinology, Hôpital Nord, CHU Saint-Etienne (France)
  2. 2Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, CHU Lyon (France)
  3. 3Institute of Cardiovascular and Metabolic Diseases, CHU Rangueil (France)
  4. 4Grenoble Teaching Hospital, CHU Hôpital Sud, Echirolles (France)
  5. 5Department of Rheumatology, Hôpital Nord, CHU Saint-Etienne (France),


Background and Objectives This study evaluates clinical and biological markers of rheumatoid arthritis (RA) severity including matrix metalloproteinase (MMP-3) and Porphyromonas gingivalis (P. gingivalis) serology during infliximab treatment and highlights predictive factors of response to infliximab.

Materials and Methods Joint damage and severe periodontal disease were assessed in 101 RA patients included in this study. DAS28, anti-citrullinated protein antibodies (ACPA), anti-P. gingivalis antibody, and MMP-3 were monitored before and at 6 months of infliximab therapy. ACPA, anti-P. gingivalis antibody, and MMP-3 were determined by ELISA.

Results At baseline, ACPA titers were associated with anti-P. gingivalis LPS-specific antibodies titers (P < 0.05). Anti-P. gingivalis antibodies were not significantly correlated with clinical, biological, or destruction parameters of RA disease. At 6 months of infliximab therapy, MMP-3 level decreased (from 119 ± 103 ng/ml to 62.44 ± 52 ng/ml; P < 0.0001), whereas P. gingivalis antibody levels remained at the same level. DAS28 and inflammation markers (CRP and ESR) also decreased significantly during infliximab therapy (P < 0.05) as ACPA levels (P < 0.001). Only high MMP-3 level at baseline was associated with infliximab efficacy (P < 0.01).

Conclusions MMP-3 level can be a useful marker of the efficacy of infliximab in RA patients. The treatment did not affect anti- P. gingivalis antibodies.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.